

DIAGNOSE THE ENTIRE CORONARY VASCULATURE

for individualized patient management and improved quality of life

DIAGNOSING CORONARY MICROVASCULAR DYSFUNCTION WITH THE PRESSUREWIRE™ X GUIDEWIRE

Go Beyond the Angiogram


Angiography doesn't tell you the full story. Diagnose both epicardial and microvascular disease with the PressureWire™ X Guidewire.^{1,2}

- About **60%** of all elective patients undergoing angiography suffer from ischemia and no obstructive coronary artery disease (INOCA).^{3,4}
- Half of this patient population might have microvascular angina (MVA) due to coronary microvascular dysfunction (CMD).⁴
- With the PressureWire™ X Guidewire, you can diagnose this group of patients by measuring the index of microvascular resistance (IMR) and coronary flow reserve (CFR).



Improving Quality of Life for CMD Patients

The CorMicA trial provides a hypothesis-generating diagnostic and treatment approach that improved quality of life for patients with INOCA at 1 year following invasive coronary angiography.^{2,5}



- Stratified medical therapy led to sustained angina improvement and better quality of life.
- Guideline-based medical therapy and changes in lifestyle are indicated in patients with abnormal CFR (<2.0) and/or abnormal IMR (≥25).

1. Tonino, P. A. et al. (2009). Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. *The New England Journal of Medicine*. 2009; 360; 213-224. 2. Ford, T. et al. (2018). Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. *Journal of the American College of Cardiology*. 2018; 72; 2841-2855. 3. Patel, M. et al. (2010). Low diagnostic yield of elective coronary angiography. *The New England Journal of Medicine*. 2010; 363; 498. 4. Maas, A. et al. (2019). Microvascular Angina: Diagnosis, Assessment, and Treatment. *European Medical Journal, Interventional Cardiology*. Reprints of EMJ Int Cardiol. 2019 Suppl 1. 2019; 7; 2-17. 5. Berry, C. and Ford, T. (2019). How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial. *Interv Cardiol*. 2019; 14(2); 76-82.

Information contained herein for **DISTRIBUTION** in Australia and New Zealand ONLY.



Guidelines Recommend Guidewire-Based Measurements

The ESC guidelines¹ 2019 were updated accordingly to include an increased focus on microvascular disease.

RECOMMENDATIONS	CLASS ^a	LEVEL ^b
Guidewire-based CFR and/or microcirculatory resistance measurements should be considered in patients with persistent symptoms, but coronary arteries that are either angiographically normal or have moderate stenosis with preserved iwFR/FFR.	IIa	B

CFR = coronary flow reserve; CMR = cardiac magnetic resonance; ECG = electrocardiogram; FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; LAD = left anterior descending; PET = positron emission tomography.

a Class of recommendation.


b Level of evidence.

Diagnose CMD with the PressureWire™ X Guidewire

The Abbott PressureWire™ X Guidewire with the Coroventis[‡] CoroFlow[‡] Cardiovascular System is a unique platform for assessment of epicardial and microvascular physiology.^{2,3} This unique, easy-to-use combination will provide you with the critical information you need to deliver individualized patient management.

KEY FEATURES^{4,5}

- Assess epicardial physiology with FFR or RFR
- Assess coronary microvascular dysfunction with IMR and CFR
- Communicate wirelessly with the PressureWire™ X Guidewire and the Wi-Box



REORDER NUMBER	DESCRIPTION
C12059	PressureWire™ X Wireless FFR Guidewire, 175 cm
C12783	Wi-Box
12000	CoroFlow [‡] Cardiovascular System
12011	Coro PC Workstation
12012	Coro All-in-One Touch Screen PC / Mobile PC
12012-01	Coro Mobile Cart

1. Juhani Knuuti et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European Heart Journal* 2019. 2. Tonino, P. A. et al. (2009). Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. *The New England Journal of Medicine*. 2009; 360; 213-224. 3. Ford, T. et al. (2018). Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. *Journal of the American College of Cardiology*. 2018; 72; 2841-2855. 4. CoroFlow Instructions for Use. 5. PressureWire X Guidewire Instructions for Use.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at efu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for DISTRIBUTION in Australia and New Zealand ONLY.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Medical Australia: 299 Lane Cove Road, Macquarie Park NSW 2113. Phone: 1800 550 939

Abbott Medical New Zealand: Grd Flr, Bldg D, 4 Pacific Rise, Mount Wellington Auckland 1060. Phone: 0800 827 285

™ Indicates a trademark of the Abbott Group of Companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

©2020 Abbott. All rights reserved. ANZ CP0414-EN 06/20